Fibromyalgia

You have full text access to this OnlineOpen article

The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity

  1. Frederick Wolfe1,*,
  2. Daniel J. Clauw2,¶,
  3. Mary-Ann Fitzcharles3,‖,
  4. Don L. Goldenberg4,††,
  5. Robert S. Katz5,
  6. Philip Mease6,
  7. Anthony S. Russell7,‡‡,
  8. I. Jon Russell8,§§,
  9. John B. Winfield9,¶¶,
  10. Muhammad B. Yunus10,‖‖

Article first published online: 23 FEB 2010

DOI: 10.1002/acr.20140

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 62, Issue 5, pages 600–610, May 2010

Additional Information

How to Cite

Wolfe, F., Clauw, D. J., Fitzcharles, M.-A., Goldenberg, D. L., Katz, R. S., Mease, P., Russell, A. S., Russell, I. J., Winfield, J. B. and Yunus, M. B. (2010), The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care Res, 62: 600–610. doi: 10.1002/acr.20140

Author Information

  1. 1

    National Data Bank for Rheumatic Diseases and University of Kansas School of Medicine, Wichita

  2. 2

    University of Michigan Medical School, Ann Arbor

  3. 3

    Montreal General Hospital and McGill University, Montreal, Quebec, Canada

  4. 4

    Newton-Wellesley Hospital, Tufts University School of Medicine, Boston, Massachusetts

  5. 5

    Rush University Medical Center, Chicago, Illinois

  6. 6

    Seattle Rheumatology Associates and Swedish Medical Center, Seattle, Washington

  7. 7

    University of Alberta, Edmonton, Alberta, Canada

  8. 8

    University of Texas Health Sciences Center, San Antonio

  9. 9

    University of North Carolina, Chapel Hill

  10. 10

    The University of Illinois College of Medicine, Peoria

  1. Dr. Clauw has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Pfizer, Lilly, Forest, Cypress Biosciences, Pierre Fabre, UCB, and AstraZeneca.

  2. ‖

    Dr. Fitzcharles has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Pfizer, Lilly, and Boehringer Ingelheim, and has given expert testimony for various medicolegal and law firms and received a fee.

  3. ††

    Dr. Goldenberg has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Forest, Pfizer, and Lilly.

  4. ‡‡

    Dr. Anthony S. Russell has received consultant fees (less than $10,000 each) from Amgen/Wyeth, Schering-Plough, UCB, and Abbott Canada, and speaking fees (less than $10,000 each) from Roche and BMS.

  5. §§

    Dr. I. Jon Russell has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Johnson & Johnson and UCB, and (more than $10,000 each) from Pfizer, Lilly, and Jazz.

  6. ¶¶

    Dr. Winfield has received consultant fees, speaking fees, and/or honoraria (more than $10,000 each) from Lilly, Pfizer, Forest, and Jazz, and has given expert testimony for medicolegal and various law firms and received a fee.

  7. ‖‖

    Dr. Yunus has received speaking fees (more than $10,000) from Forest Laboratories.

*National Data Bank for Rheumatic Diseases, 1035 North Emporia, Suite 288, Wichita, KS 67214

Publication History

  1. Issue published online: 29 APR 2010
  2. Article first published online: 23 FEB 2010
  3. Accepted manuscript online: 23 FEB 2010 12:00AM EST
  4. Manuscript Accepted: 10 FEB 2010
  5. Manuscript Received: 24 AUG 2009

Funded by

  • Lilly Research Laboratories

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (137K)

REFERENCES

  • 1
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72.
    Direct Link:
  • 2
    Fitzcharles MA, Boulos P. Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. Rheumatology (Oxford) 2003; 42: 263–7.
  • 3
    Buskila D, Neumann L, Sibirski D, Shvartzman P. Awareness of diagnostic and clinical features of fibromyalgia among family physicians. Fam Pract 1997; 14: 238–41.
  • 4
    Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford L, Glass JM, et al, for the OMERACT Fibromyalgia Working Group. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol 2009; 36: 2318–29.
  • 5
    Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Simon LS, Martin SA, et al. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol 2009; 36: 2330–4.
  • 6
    Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 2005; 75: 6–21.
  • 7
    Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, et al. Fibromyalgia syndrome. J Rheumatol 2007; 34: 1415–25.
  • 8
    Crofford LJ, Clauw DJ. Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? [editorial]. Arthritis Rheum 2002; 46: 1136–8.
    Direct Link:
  • 9
    Wolfe F, Michaud K. Outcome and predictor relationships in fibromyalgia and rheumatoid arthritis: evidence concerning the continuum versus discrete disorder hypothesis. J Rheumatol 2009; 36: 831–6.
  • 10
    Wolfe F. When to diagnose fibromyalgia. Rheum Dis Clin North Am 1994; 20: 485–501.
  • 11
    Wolfe F. Pain extent and diagnosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. J Rheumatol 2003; 30: 369–78.
  • 12
    Wolfe F, Michaud K, Pincus T. Development and validation of the Health Assessment Questionnaire II: a revised version of the Health Assessment Questionnaire. Arthritis Rheum 2004; 50: 3296–305.
    Direct Link:
  • 13
    Berk RA. Data mining within a regression framework. In: MaimonO, RokachL, editors. Data mining and knowledge discovery handbook. New York: Springer; 2005. p. 231–55.
  • 14
    Atkinson EJ, Therneau TM. An introduction to recursive partitioning using the RPART routines. Rochester: Mayo Foundation; 2000.
  • 15
    Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 1981; 11: 151–71.
  • 16
    Cohen ML, Quintner JL. Fibromyalgia syndrome, a problem of tautology. Lancet 1993; 342: 906–9.
  • 17
    Macfarlane GJ, Croft PR, Schollum J, Silman AJ. Widespread pain: is an improved classification possible? J Rheumatol 1996; 23: 1628–32.
  • 18
    Macfarlane GJ. Chronic widespread pain and fibromyalgia: should reports of increased mortality influence management? Curr Rheumatol Rep 2005; 7: 339–41.
  • 19
    Moldofsky H. The significance of the sleeping-waking brain for the understanding of widespread musculoskeletal pain and fatigue in fibromyalgia syndrome and allied syndromes. Joint Bone Spine 2008; 75: 397–402.
  • 20
    Hieblinger R, Coenen M, Stucki G, Winkelmann A, Cieza A. Validation of the International Classification of Functioning, Disability and Health core set for chronic widespread pain from the perspective of fibromyalgia patients. Arthritis Res Ther 2009; 11: R67.
  • 21
    Macfarlane GJ, Jones GT, Knekt P, Aromaa A, McBeth J, Mikkelsson M, et al. Is the report of widespread body pain associated with long-term increased mortality? Data from the Mini-Finland Health Survey. Rheumatology (Oxford) 2007; 46: 805–7.
  • 22
    Macfarlane GJ, Pye SR, Finn JD, Wu FC, Silman AJ, Bartfai G, et al. Investigating the determinants of international differences in the prevalence of chronic widespread pain: evidence from the European Male Ageing Study. Ann Rheum Dis 2009; 68: 690–5.
View Full Article with Supporting Information (HTML) Get PDF (137K)